Summary
Itraconazole, a triazole antifungal agent, has been reported to reverse drug resistance against daunorubicin in acute leukemia. In a subanalysis from a double-blind, placebo-controlled trial examining the effects of itraconazole on the prevention of fungal infections in neutropenic patients, we studied the effects of itraconazole on remission rate and disease-free survival in patients with acute lymphoblastic (ALL) and acute myelogenous leukemia (AML) receiving remission induction treatment schedules containing daunorubicin (DNR). Eleven ALL and 17 AML patients received itraconazole and 12 ALL and 25 AML patients were given placebo. Among AML patients the remission rate was slightly higher in the itraconazole group, whereas the disease-free survival was higher mong ALL patients given itraconazole. In AML patients DFS was comparable in both groups but the number of high-risk patients in the itraconazole group was higher. These preliminary results may suggest a role for itraconazole in reversing multidrug resistance. Larger trials, however, are required to substantiate these findings and to correlate them with its in vitro effects on multidrug resistance.
Similar content being viewed by others
References
Bradley G, Juranka PF, Ling V (1988) Mechanisms of multi-drug resistance. Biochim Biophys Acta 948:87–128
Cutsem JF van, Van Gerven F, Van de Ven MA, Borger M, Janssen PAJ (1984) Itraconazole, a new triazole that is orally active against aspergillosis. Antimicrob Agents Chemother 26:527–534
Gottesman MM, Pastan I (1988) Resistance to multiple chemotherapeutic agents in human cancer cells. Trends Pharmacol Sci 9:54–58
Gupta S, Kim J, Gollapudi S (1991) Reversal of daunorubicin resistance in P388/ADSR cells by itraconazole. J Clin Invest 87:1467–1469
Juranka PF, Zastawny RL, Ling V (1989) P-glycoprotein: multidrug resistance and a superfamily of membrane-associated transport proteins. Fed Am Soc Exp Biol J 3:2583–2592
Lazo JS, Bahnson RR (1989) Pharmacological modulators of DNA-interactive antitumor drugs. Trends Pharmacol Sci 10:369–373
Slater LM, Sweet P, Stupecky M, Gupta S (1986) Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br J Cancer 54:235–239
Slater LM, Sweet P, Stupecky M, Gupta S (1986) Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 77:1405–1408
Van't Wout JW, Novakova I, Verhagen CAH, Fibbe WE, De Pauw BE, Van der Meer JW (1991) The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect 2:45–52
Vreugdenhil G, Van Dijke BJ, Donnelly P, et al. (1992) A double-blind placebo-controlled study of itraconazole in the prevention of fungal infections in acute leukemia. 7th international symposium on infections in the immunocompromised host, Boulder, Colorado, June 21–24, 1992 (abstract no. 57)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vreugdenhil, G., Raemaekers, J.M.M., van Dijke, B.J. et al. Itraconazole and multidrug resistance: Possible effects on remission rate and disease-free survival in acute leukemia. Ann Hematol 67, 107–109 (1993). https://doi.org/10.1007/BF01701730
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01701730